CClinicalTrials.gg
CompletedNCT03414372Updated Mar 6, 2023Results posted

Tough Talks: A Disclosure Intervention for HIV+ Young Men Who Have Sex With Men (YMSM)

An interventional study of Tough Talks Online and Tough Talks Clinic in Hiv, HIV/AIDS and Disclosure, sponsored by University of North Carolina, Chapel Hill. Completed at 1 site in United States. Open to male participants aged 16 Years to 29 Years. Per ClinicalTrials.gov, last updated 2023-03-06.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
16 Years to 29 Years
Sex
Male
01

Study summary

Tough Talks is a virtual reality based HIV disclosure intervention that allows HIV+ individuals to practice disclosing to romantic partners. Tough Talks allows participants to have the opportunity to practice disclosing using a variety of strategies and experience different outcomes including acceptance, confusion, lack of HIV knowledge, and rejection.

Read the detailed description

During Phase I of this project, the investigators developed an iPad based virtual reality system that features three avatars, two virtual locations and three disclosure scenarios which represent a variety of common disclosure experiences and contexts experienced by YMSM. In Phase II the investigators will further enhance Tough Talks and develop a full-feature automated version to test via a multi-site, randomized controlled trial (RCT) through the newly created Center for Innovative Technologies (iTech) across the Prevention and Care Continuum, an NIH-funded center to support adolescent HIV research.

02

Conditions studied

  • Hiv
  • HIV/AIDS
  • Disclosure

Keywords

  • MSM
  • HIV
  • disclosure
  • eHealth
  • virtual reality
03

Who can participate

Ages eligible
16 Years to 29 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • 16-29 years
  • assigned male at birth
  • male identified
  • HIV infected
  • Owns a mobile device or has access to a laptop or desktop computer
  • able to understand, read, and speak English
  • Reports 1 or more episodes of anal intercourse with a male partner in the last 6 months

Exclusion criteria

Exclusion Criteria:

  • HIV negative
  • assigned female at birth
  • 15 or younger
  • 30 or older
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    Tough Talks Online

    Participants will use Tough Talks Online

    Behavioral: Tough Talks Online

  • Experimental
    Tough Talks Clinic

    Participants will use receive Tough Talks in a clinic

    Behavioral: Tough Talks Clinic

  • Placebo comparator
    Standard of Care

    Participants will receive the standard of care (SOC).

    Behavioral: Standard of Care

Interventions

  • BehavioralTough Talks Online

    Those randomized to the online condition will receive information about how to access Tough Talks online and be given their unique log-in and password information and information on how to contact study personnel for any technical issues. Arm 1 participants will have 24-hour access to all of the intervention features and will be able to access the program for additional sessions at any time. Study staff will provide reminders using text or email (participant preference) if they have not accessed the intervention at the specified time intervals.

    Also known as: Tough Talks

  • BehavioralTough Talks Clinic

    Those randomized to the in-clinic condition (Arm 2) will immediately begin the Tough Talks intervention. Study staff will ensure participants are logged on and will also be available to answer technical issues should they arise. After completion, those in this arm will have an in-person follow-up visit scheduled for approximately two weeks. The in-person sessions were adapted to be delivered via Zoom or a similar HIPAA compliant platform due to the COVID-19 pandemic.

  • BehavioralStandard of Care

    Those randomized to the control arm (SOC) will receive a paper-based disclosure informational packet based on available Centers of Disease Control (CDC) guidance. At one-month, all participants will complete an online survey to assess intervention acceptability as well as to assess Social Cognitive Theory (SCT model) constructs.

05

What researchers measure

Primary outcomes

  1. Number of Participants With Suppressed Viral Load

    Chart review or drawn for study. Viral load suppression will be defined as HIV RNA \< lower limit of detection as per the laboratory at each clinical site.

    Time frame: Month 6

Secondary outcomes

  1. Number of Participants Who Had Condomless Anal Intercourse With a Potentially Susceptible Partner

    Number of participants at month 6 with \>/= 1 act of condomless anal intercourse with a partner who is not known to be HIV-positive within the last 3 months.

    Time frame: Month 6

  2. Mean Intention to Disclose Score

    Measured using the Intention to Disclose scale which asks a single item: "I plan on telling my HIV status to all of my new partners before we have sex" and is rated using a 5-point Likert-type response scale. Scores range from 1 to 5 where '1' is "Strongly agree" and '5' is "Strongly disagree. "Lower scores indicate increased intention to disclose.

    Time frame: Month 6

  3. Mean Disclosure Self-Efficacy Score

    Measure of perceived ability to disclose HIV-seropositive status to casual sex partners in six scenarios. Scores were summed with higher scores indicating increased perceived ability to disclose. Six Questions were asked using a 5 point Likert Scale: 1=Absolutely sure I cannot; 2=Somewhat sure I cannot; 3=Not sure; 4=Somewhat sure I can; and 5=Absolutely sure I can. Scores range from 6-30.

    Time frame: Month 6

  4. Mean Consequences of Disclosure (Cost) Score

    Measure of a participant's perceived negative consequences of disclosing of their HIV status to a partner (e.g., "Relationship would get bad", "Person would not want to be around me"), with higher scores indicating higher perceived negative consequences of disclosure. Eight Questions rated using a 4-point Likert Scale 1=Strongly disagree 2=Disagree 3=Agree 4=Strongly Agree. Scores range from 8 to 32.

    Time frame: Month 6

  5. Mean Consequences of Disclosure (Rewards) Score

    Measure of a participant's perceived positive consequences of disclosing of their HIV status to a partner (e.g., "Keep them safe from HIV", "Improve the relationship"), with higher scores indicating higher perceived positive consequences of disclosure. Ten Questions rated using a 4-point Likert Scale 1=Strongly disagree; 2=Disagree; 3=Agree; and 4=Strongly Agree. Scores range from 10-40.

    Time frame: Month 6

  6. Mean Disclosure Self-Regulation (Family) Score

    Measured using a single question: "How many of your immediate family members are not aware of your HIV status but to whom you want to disclose?" and rated using a 5-point Likert Scale: 1=None; 2=Some, but less than half; 3=About half; 4=More than half; and 5=All. Scores range from 1 to 5 with lower scores indicating increased disclosure behaviors.

    Time frame: Month 6

  7. Mean Disclosure Self-Regulation (Peers) Score

    Measured using a single question: "How many of your peers are not aware of your HIV status but to whom you want to disclose?" and rated using a 5-point Likert Scale: 1=None; 2=Some, but less than half; 3=About half; 4=More than half; and 5=All. Scores range from 1 to 5 with lower scores indicating increased disclosure behaviors.

    Time frame: Month 6

  8. Mean Disclosure Self-Regulation (Sexual Partners) Score

    Measured using a single question: "How many of your current and past sexual partners are not aware of your HIV status but to whom you want to disclose?" and rated using a 5-point Likert Scale: 1=None; 2=Some, but less than half; 3=About half; 4=More than half; and 5=All. Scores range from 1 to 5 with lower scores indicating increased disclosure behaviors.

    Time frame: Month 6

  9. Mean Disclosure Outcome Expectations (Self-Evaluative) Score

    Measure of how a participant anticipates their behavior impacts their feelings or assessment of HIV protective behaviors. Higher scores indicate a more favorable/stronger evaluation/endorsement of HIV protective behaviors. Participant's self-evaluation based on six questions using a 5-point Likert scale (1, strongly disagree to 5, strongly agree) ranging from 5 to 30.

    Time frame: Month 6

  10. Mean Disclosure Outcome Expectations (Hedonistic) Score

    Measure of how a participant anticipates their behavior impacts their feelings or assessment of sexual pleasure or sensuality. Lower scores indicate a more favorable/stronger evaluation/endorsement of HIV protective behaviors. Participant's self-evaluation based on three questions using a 5-point Likert scale (1, strongly disagree to 5, strongly agree) ranging from 3 to 15.

    Time frame: Month 6

06

Results

Posted Mar 6, 2023

Participant flow

Participant flow — Overall Study
MilestoneTough Talks OnlineTough Talks ClinicStandard of Care
Started535152
Completed434244
Not completed1098

Outcome measures

PrimaryNumber of Participants With Suppressed Viral Load

Chart review or drawn for study. Viral load suppression will be defined as HIV RNA \< lower limit of detection as per the laboratory at each clinical site.

Time frame:
Month 6
Reported as:
Count of participants · Participants
Number of Participants With Suppressed Viral Load
ParticipantsTough Talks OnlineTough Talks ClinicStandard of Care
Number of Participants With Suppressed Viral Load293130
SecondaryNumber of Participants Who Had Condomless Anal Intercourse With a Potentially Susceptible Partner

Number of participants at month 6 with \>/= 1 act of condomless anal intercourse with a partner who is not known to be HIV-positive within the last 3 months.

Time frame:
Month 6
Reported as:
Count of participants · Participants
Number of Participants Who Had Condomless Anal Intercourse With a Potentially Susceptible Partner
ParticipantsTough Talks OnlineTough Talks ClinicStandard of Care
Number of Participants Who Had Condomless Anal Intercourse With a Potentially Susceptible Partner1168
SecondaryMean Intention to Disclose Score

Measured using the Intention to Disclose scale which asks a single item: "I plan on telling my HIV status to all of my new partners before we have sex" and is rated using a 5-point Likert-type response scale. Scores range from 1 to 5 where '1' is "Strongly agree" and '5' is "Strongly disagree. "Lower scores indicate increased intention to disclose.

Time frame:
Month 6
Reported as:
Mean · score on a scale
Mean Intention to Disclose Score
score on a scaleTough Talks OnlineTough Talks ClinicStandard of Care
Mean Intention to Disclose Score1.45 ± 0.501.33 ± 0.471.15 ± 0.36
SecondaryMean Disclosure Self-Efficacy Score

Measure of perceived ability to disclose HIV-seropositive status to casual sex partners in six scenarios. Scores were summed with higher scores indicating increased perceived ability to disclose. Six Questions were asked using a 5 point Likert Scale: 1=Absolutely sure I cannot; 2=Somewhat sure I cannot; 3=Not sure; 4=Somewhat sure I can; and 5=Absolutely sure I can. Scores range from 6-30.

Time frame:
Month 6
Reported as:
Mean · score on a scale
Mean Disclosure Self-Efficacy Score
score on a scaleTough Talks OnlineTough Talks ClinicStandard of Care
Mean Disclosure Self-Efficacy Score22.89 ± 7.6923.03 ± 6.5425.64 ± 7.24
SecondaryMean Consequences of Disclosure (Cost) Score

Measure of a participant's perceived negative consequences of disclosing of their HIV status to a partner (e.g., "Relationship would get bad", "Person would not want to be around me"), with higher scores indicating higher perceived negative consequences of disclosure. Eight Questions rated using a 4-point Likert Scale 1=Strongly disagree 2=Disagree 3=Agree 4=Strongly Agree. Scores range from 8 to 32.

Time frame:
Month 6
Reported as:
Mean · score on a scale
Mean Consequences of Disclosure (Cost) Score
score on a scaleTough Talks OnlineTough Talks ClinicStandard of Care
Mean Consequences of Disclosure (Cost) Score23.40 ± 8.1924.07 ± 8.8419.20 ± 8.95
SecondaryMean Consequences of Disclosure (Rewards) Score

Measure of a participant's perceived positive consequences of disclosing of their HIV status to a partner (e.g., "Keep them safe from HIV", "Improve the relationship"), with higher scores indicating higher perceived positive consequences of disclosure. Ten Questions rated using a 4-point Likert Scale 1=Strongly disagree; 2=Disagree; 3=Agree; and 4=Strongly Agree. Scores range from 10-40.

Time frame:
Month 6
Reported as:
Mean · score on a scale
Mean Consequences of Disclosure (Rewards) Score
score on a scaleTough Talks OnlineTough Talks ClinicStandard of Care
Mean Consequences of Disclosure (Rewards) Score32.22 ± 6.0234.18 ± 6.1534.31 ± 5.35
SecondaryMean Disclosure Self-Regulation (Family) Score

Measured using a single question: "How many of your immediate family members are not aware of your HIV status but to whom you want to disclose?" and rated using a 5-point Likert Scale: 1=None; 2=Some, but less than half; 3=About half; 4=More than half; and 5=All. Scores range from 1 to 5 with lower scores indicating increased disclosure behaviors.

Time frame:
Month 6
Reported as:
Mean · score on a scale
Mean Disclosure Self-Regulation (Family) Score
score on a scaleTough Talks OnlineTough Talks ClinicStandard of Care
Mean Disclosure Self-Regulation (Family) Score2.57 ± 1.532.51 ± 1.482.59 ± 1.58
SecondaryMean Disclosure Self-Regulation (Peers) Score

Measured using a single question: "How many of your peers are not aware of your HIV status but to whom you want to disclose?" and rated using a 5-point Likert Scale: 1=None; 2=Some, but less than half; 3=About half; 4=More than half; and 5=All. Scores range from 1 to 5 with lower scores indicating increased disclosure behaviors.

Time frame:
Month 6
Reported as:
Mean · score on a scale
Mean Disclosure Self-Regulation (Peers) Score
score on a scaleTough Talks OnlineTough Talks ClinicStandard of Care
Mean Disclosure Self-Regulation (Peers) Score2.49 ± 1.492.33 ± 1.182.67 ± 1.49
SecondaryMean Disclosure Self-Regulation (Sexual Partners) Score

Measured using a single question: "How many of your current and past sexual partners are not aware of your HIV status but to whom you want to disclose?" and rated using a 5-point Likert Scale: 1=None; 2=Some, but less than half; 3=About half; 4=More than half; and 5=All. Scores range from 1 to 5 with lower scores indicating increased disclosure behaviors.

Time frame:
Month 6
Reported as:
Mean · score on a scale
Mean Disclosure Self-Regulation (Sexual Partners) Score
score on a scaleTough Talks OnlineTough Talks ClinicStandard of Care
Mean Disclosure Self-Regulation (Sexual Partners) Score2.08 ± 1.401.68 ± 1.031.71 ± 1.22
SecondaryMean Disclosure Outcome Expectations (Self-Evaluative) Score

Measure of how a participant anticipates their behavior impacts their feelings or assessment of HIV protective behaviors. Higher scores indicate a more favorable/stronger evaluation/endorsement of HIV protective behaviors. Participant's self-evaluation based on six questions using a 5-point Likert scale (1, strongly disagree to 5, strongly agree) ranging from 5 to 30.

Time frame:
Month 6

No measurements were reported for this outcome.

SecondaryMean Disclosure Outcome Expectations (Hedonistic) Score

Measure of how a participant anticipates their behavior impacts their feelings or assessment of sexual pleasure or sensuality. Lower scores indicate a more favorable/stronger evaluation/endorsement of HIV protective behaviors. Participant's self-evaluation based on three questions using a 5-point Likert scale (1, strongly disagree to 5, strongly agree) ranging from 3 to 15.

Time frame:
Month 6

No measurements were reported for this outcome.

Adverse events

Collected over From signing of informed consent through study completion, a total of up to 7 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tough Talks Online0/53 (0%)0/53 (0%)0/53 (0%)
Tough Talks Clinic0/51 (0%)0/51 (0%)0/51 (0%)
Standard of Care1/52 (1.9%)0/52 (0%)0/52 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tough Talks OnlineTough Talks ClinicStandard of CareTotal
Mean23.19 ± 3.5023.92 ± 3.3524.23 ± 3.4623.78 ± 3.45
Sex: Female, Male
Sex: Female, Male(Participants)Tough Talks OnlineTough Talks ClinicStandard of CareTotal
Female0000
Male535152156
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tough Talks OnlineTough Talks ClinicStandard of CareTotal
Hispanic or Latino15131341
Not Hispanic or Latino383839115
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tough Talks OnlineTough Talks ClinicStandard of CareTotal
American Indian or Alaska Native1012
Asian1203
Native Hawaiian or Other Pacific Islander0101
Black or African American32332893
White13111337
More than one race411015
Unknown or Not Reported2305
Region of Enrollment
Region of Enrollment(Participants)Tough Talks OnlineTough Talks ClinicStandard of CareTotal
United States535152156
07

Study locations

1 site
  • UNC Chapel Hill
    Chapel Hill, North Carolina 27599, United States
08

References and documents

Publications

  • Hightow-Weidman LB, Muessig K, Soberano Z, Rosso MT, Currie A, Adams Larsen M, Knudtson K, Vecchio A. Tough Talks Virtual Simulation HIV Disclosure Intervention for Young Men Who Have Sex With Men: Development and Usability Testing. JMIR Form Res. 2022 Sep 8;6(9):e38354. doi: 10.2196/38354. PubMed 36074551 ↗

Study documents

  • Protocol and statistical analysis plan · May 13, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — The investigators are not planning on making individual participant data available to other researchers.

09

Registry details

Key details

Study ID
NCT03414372
Lead sponsor
University of North Carolina, Chapel Hill
Collaborators
Virtually Better, Inc., National Institute of Mental Health (NIMH)
Responsible party
Sponsor
First posted
Jan 29, 2018
Start date
May 7, 2019
Primary completion
Apr 7, 2022
Completion
Apr 7, 2022
Results posted
Mar 6, 2023
Last update
Mar 6, 2023

Study contacts

Kate Muessig, PhD
principal investigator · UNC-Chapel Hill
Lisa Hightow-Weidman, MD
principal investigator · UNC-Chapel Hll

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion